Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score:19

learn.astct.org

ASTCT Learning Center: GVHD - 6 days

Mashup Score:19

GVHD Contains 1 Component(s)Join Dr. Kirk R. Schultz from the University of British Columbia as he discusses new and emerging therapies in cGvHD. In...

Sclerodermatous and pulmonary chronic graft-versus-host disease (cGVHD) is highly resistant to therapy. Previous studies suggest these fibrotic syndromes are...

Alina Markova, MD, discusses the rationale for assessing topical ruxolitinib INCB018424 phosphate 1.5% cream in patients with non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host...

Yi-Bin Chen, MD, shares insight on unmet needs and the future treatment landscape for patients with chronic GVHD and steroid-refractory...

Uday R. Popat, MD, spoke about how well post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease was performed in this...

The overall response rate achieved with ruxolitinib at day 28 proved to be higher than what was achieved with best available therapy in patients...

  • 1528043002798739457 Profile photo of Madelyn

    The overall response rate achieved with ruxolitinib at day 28 proved to be higher than what was achieved with best available therapy in patients with steroid-refractory acute graft-vs-host disease, irrespective of organ involvement. #oncology #GVHD https://t.co/7fZwMKrUQB - view on twitter

The overall response rate achieved with ruxolitinib at day 28 proved to be higher than what was achieved with best available therapy in patients...

A panel of experts in stem cell transplant and cellular immunotherapy builds a lively discussion on current and emerging treatment options for the management...